Costs and resource use of mild persistent asthma patients initiated on controller therapy

Journal of Asthma

Volumn 45, Issue 4, 2008, Pages 293-299

  Colice, Gene L ^a   Yu, Andrew P ^b   Ivanova, Jasmina I ^b   Hsieh, Matthew ^b   Birnbaum, Howard G ^b   Lage, Maureen J ^c   Brewster, Corrine ^d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b ANALYSIS GROUP   (United States)

^c HealthMetrics Outcomes Research LLC   (United States)

^d Teva Specialty Pharmaceuticals   (United States)

Author keywords

Asthma related costs; Asthma related resource use; Inhaled corticosteroids; Leukotriene modifiers; Mild persistent asthma

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR AFFECTING AGENT; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; ALGORITHM; ARTICLE; ASTHMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST CONTROL; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; RANK SUM TEST; TREATMENT OUTCOME; COMORBIDITY; DRUG COMBINATION; ECONOMICS; HEALTH CARE PLANNING; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; UTILIZATION REVIEW;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; LEUKOTRIENE ANTAGONISTS; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 43049134880     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900801911178     Document Type: Article

References (40)

1. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. NHLBI, 1997.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI, 2006.
3. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment. BMJ 2003; 326:621-625.
4. Ducharme FM, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systemic Reviews 00075320, 2004.
5. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352:1519-1528.
6. The American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356:2027-2039.
7. Kluijver J, Evertse CE, Schrumpf JA, van der Veen H, Zwinderman AH, Hiemstra PS, et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma. Am J Respir Crit Care Med 2002;166:294-300.
8. Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ. Inhaled fluticasone propionate by Diskus in the treatment of asthma. Chest 2003; 124:1584-1593.
9. Thomas M, Cleland J, Price D. Database studies in asthma pharmacoeconomics. Expert Opin Pharmocother 2003; 4:351-358.
10. Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med 2006; 48:794-802.
11. Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB. Use of inhaled corticosteroids and health care costs in mild persistent asthma. J Asthma 2007; 44:479-483.
12. National Committee for Quality Assurance. Use of appropriate medications for people with asthma. HEDIS 2005, vol 2. Technical Specifications. Washington, DC.
13. Leidy NK, Paramore LC, Watrous M, Doyle J, Zeiger RS. Development of an algorithm for estimating asthma severity from an administrative cost database. Value Health 1999; 2:394.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-383.
15. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-1079.
16. Wolfe J, Rooklin A, Grady J, Munk ZM, Stevens A, Prillaman B, Duke S, Harding S. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol. 2000; 105:1153-1161.
17. Nathan RA, Li JT, Finn A, Jones R, Payne JE, Wolford JP, Harding SM. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000;118:296-302.
18. ZuWallack R, Adelglass J, Clifford DP, Duke SP, Wire PD, Faris M, Harding SM. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000; 118:303-312.
19. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001;164:1392-1397.
20. Morbidity and Mortality Weekly Report. Asthma prevalence and control characteristics by race/ethnicity - United States, 2002. Morbid Mortal Wkly Rep MMWR 2004; 53:7.
21. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002; 109:S482-S489.
22. Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol 2002; 109:264-270.
23. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12:1322-1326.
24. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity. Eur Respir J 2002; 19:61-67.
25. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111:1212-1218.
26. Sullivan SD, Buxton M, Andersson F, Lamm CJ, Liljas B, Chen YZ, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 12:1229-1236.
27. O'Byrne P, Cuddy L, Taylor DW, Birch S, Morris J, Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J 1996; 3:169-175.
28. O'Connor RD, Parasuraman B, Roberts C, Leibman C. Inhaled corticosteroids vs leukotriene receptor antagonists. Ann Allergy Asthma Immunol 2006; 97:236-243.
29. Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004; 92:523-529.
30. Balkrishnan R, Nelson LM, Kulkarni AS, Pleasants RA, Whitmire JT, Schechter MS. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population. J Asthma 2005; 42:35-40.
31. Friedman HS, Yawn BP. Resource utilization in asthma. Curr Med Res Opin 2007; 23:427-434.
32. Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS, et al. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol 2007; 119:916-923.
33. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98:1051-1057.
34. Schatz M, Zeiger RS, Vollmer WM, Mosen D, Apter AJ, Stibolt TB, et al. Validation of a β-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006;117:995-1000.
35. Schatz M, Zeiger RS, Vollmer WM, Mosen D; Mendoza G, Apter AJ, et al. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. Chest 2006;130:43-50.
36. Schatz M, Nakahiro R, Crawford W, Mendoza G, Mosen D, Stibolt TB. Asthma quality-of-care markers using administrative data. Chest 2005;128:1968-1973.
37. Cabana MD, Slish KK, Nan B, Clark NM. Limits of the HEDIS criteria in determining asthma severity for children. Pediatrics 2004; 114:1049-1055.
38. Berger WE, Legorreta AP, Blaiss MS, Schneider EC, Luskin AT, Stempel DA, et al. The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Ann Allergy Asthma Immunol 2004; 93:538-545.
39. Fuhlbrigge AL, Carey VJ, Finkelstein JA, Lozano P, Inui TS, Weiss ST, et al. Validity of the HEDIS criteria to identify children with persistent asthma and sustained high utilization. Am J Manag Care 2005; 11:325-330.
40. Mosen DM, Macy E, Schatz M, Mendoza G, Stibolt TB, McGaw J, et al. Howwell do the HEDIS asthma inclusion criteria identify persistent asthma. Am J Manag Care 2005; 11:650-654.